Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1.-22. (Cancelled).

23. (Currently Amended) A compound of formula I



(I)

wherein

each of R^0, R^1, R^2,and R^3 independently is hydrogen, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$, $-NR_{12}S(O)_{0-2}R_{13}$, and $-C(O)NR_{12}R_{13}$; wherein R_{12} is selected from hydrogen and C_{1-6}alkyl; and R_{13} is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl, ~~C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted C_5-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstituted or substituted amino, C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano or nitro; or~~

~~R^0 and R^1, R^1 and R^2, and/or R^2 and R^3 form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;~~

R^4 is hydrogen ~~or C_1-C_8alkyl~~;

each of R^5 and R^6 independently is hydrogen, ~~C_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, haloC_1-C_8alkyl, C_1-C_8alkoxy,~~ halogen, ~~carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro;~~ and

each of R^7, R^8, R^9, and R^{10} independently is ethoxy, ethyl, propyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, $-XR_{11}$, $-C(O)R_{11}$ and $-OXR_{11}$; wherein X is a bond, methylene or ethylene; R_{11} is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R_{11} is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino,

~~C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_6-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_6-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted C_6-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstitued or substituted amino, C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_6-C_{10}arylsulfonyl, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano or nitro;~~ wherein R^7, R^8 and R^9 independently of each other can also be hydrogen;

~~or R^7 and R^8, R^8 and R^9, and/or R^9 and R^{10} form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;~~

A is C ~~or N~~;

and salts thereof.

24. (Currently Amended) A compound of formula I according to claim 23, wherein

each of R^0 or R^2 independently is hydrogen, ~~C_1-C_8alkyl, hydroxyC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_6-C_{10}aryl, unsubstituted or substituted 5 or 6 membered~~

~~heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C_1-C_8alkoxy, haloC_1-C_8alkoxy, C_5-C_{10}aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstituted or substituted amino, C_1-C_8alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl~~;

R^1 is hydrogen, ~~C_1-C_8alkyl, hydroxyC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C_1-C_8alkoxy, haloC_1-C_8alkoxy, C_5-C_{10}aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstituted or substituted amino, C_1-C_8alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;~~

R^3 is selected from dimethyl-sulfamoyl, isobutyl-sulfamoyl, methyl-sulfamoyl, ethyl-sulfamoyl, propyl-sulfonyl, ethyl-amino-carbonyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, isopropyl-sulfamoyl, cyclohexyl-sulfonyl, cyclopropyl-methyl-sulfamoyl, cyclobutyl-sulfamoyl, isopropyl-sulfonyl.

~~hydrogen, C_1-C_8alkyl, hydroxyC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, C_1-C_8alkoxy, substituted amino, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, unsubstituted or substituted sulfamoyl;~~ or

~~each pair of adjacent substituents R^0 and R^1, or R^1 and R^2, or R^2 and R^3 is $-CH_2-NH-CO-$, $-CH_2-CH_2-NH-CO-$, $-CH_2-CO-NH-$, $-CH_2-CH_2-CO-NH-$, $-CH_2-NH-SO_2-$, $-CH_2-CH_2-NH-SO_2-$, $-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-$, $-CH_2-CH_2-CH_2-SO_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$, and such pairs wherein hydrogen in NH is replaced by C_1-C_8alkyl;~~

~~R^4 is hydrogen or C_1-C_8alkyl;~~

~~R^5 is hydrogen; C_1-C_8alkyl, halogen, haloC_1-C_8alkyl, cyano or nitro;~~

~~R^6 is hydrogen;~~

~~each of R^7 and R^9 independently is hydrogen, C_1-C_8alkyl, hydroxyC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C_1-C_8alkoxy, haloC_1-C_8alkoxy, C_5-C_{10}aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstituted or substituted amino, C_1-C_8alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;~~

~~R^8 is hydrogen, C_1-C_8alkyl, hydroxyC_1-C_8alkyl, haloC_1-C_8alkyl, C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C_1-C_8alkoxy, haloC_1-C_8alkoxy, C_5-C_{10}aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstituted or substituted amino, C_1-C_8alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and~~

~~R^{10} is C_1-C_8alkyl, hydroxyC_1-C_8alkyl, haloC_1-C_8alkyl, C_1-C_8alkoxy, unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or~~

~~each pair of adjacent substituents R^7 and R^8, or R^8 and R^9 or R^9 and R^{10}, is $-NH-CH=CH-$, $-CH=CH-NH-$, $-NH-N=CH-$, $-CH=N-NH-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-O-$, $-CH=CH-O-$, $-O-CH_2-O-$, or $-O-CF_2-O-$;~~

~~A is C or N.~~

25.-32. (Cancelled).

33. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 23, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

34. (Currently Amended) A combination comprising a therapeutically effective amount of a compound according to claim 23 and one or more further known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

35. (Previously Presented) A method for the treatment of neoplastic diseases and immune system disorders in a subject in need thereof which comprises administering an effective amount of a compound according to claim 23.

36. (Currently Amended) A method for the treatment ~~or prevention~~ of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor which comprises administering an effective amount of a compound according to claim 23.

37..(Previously Presented) A method according to claim 36, wherein the disease to be treated is a proliferative disease.

38. (Previously Presented) A method according to claim 37, wherein the proliferative disease to be treated is selected from a tumor of, breast, renal , prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas.

39. (Previously Presented) A method according to claim 35, wherein the disease to be treated is an immune disease.

40. (Previously Presented) A method to treat an inflammatory and/or immune disorder comprising administering an effective amount of a compound according to claim 23 wherein the disorder is selected from transplant rejection, allergy and autoimmune disorders mediated by immune cells including T lymphocytes, B lymphocytes, macrophages, dendritic cells, mast cells and eosinophils.

41. (Cancelled).

42. (Cancelled).

43. (New) A compound of formula I according to claim 23, selected from







,



,



,



,



,



,



,



, or



.